The last century has seen a vast increase in the incidence of malignant melanoma, both in the United States and worldwide. 1 In 2019, an estimated 96,480 cases of invasive melanoma will be diagnosed in the United States alone, resulting in over 7,000 deaths. 2 Advances in basic and translational research are essential in addressing this public health challenge. Developments in molecular biology and genomics are rapidly expanding the armamentarium of diagnostic and therapeutic tools available to facilitate the management of melanoma patients. 3 A deeper understanding of patterns of gene expression in melanoma lesions has resulted in the development of novel tests designed to both aid in the diagnosis of melanoma and to provide additional prognostic information in confirmed cases. These gene expression profiling (GEP) assays utilize a quantitative reversetranscriptase polymerase chain reaction (qRT-PCR) to determine the level of expression of key groups of signature genes. [4] [5] [6] The utility of diagnostic and prognostic GEP technology is based upon the fact that the level of expression of key genes varies between benign and malignant pigmented lesions and between malignant melanomas with lower and higher propensity for subsequent metastasis, respectively. [4] [5] [6] Depending on the specific test being utilized, the results can aid in the decision to biopsy equivocal pigmented lesions 6 , assist dermatopathologists in determining a diagnosis in cases of challenging histopathology 7 , and provide managing clinicians with further prognostic information in cases of biopsy-proven melanoma. 4 In 2018, three validated, US governmentally approved, commercially available GEP tests were each incorporated into melanoma patient management over 10,000 times in the United States. [8] [9] [10] [11] Despite the magnitude of melanoma GEP test utilization, current melanoma management guidelinesincluding those recently put forward by the American Academy of Dermatology (AAD)fail to provide guidance regarding the use of these assays across specific clinical situations. 12 Given the existing knowledge gap and the high current magnitude of utilization of these tests, there is a critical need for an evidence-based consensus statement. To meet this need, a panel of dermatologists/dermatopathologists with expertise in pigmented lesions, knowledge of the melanoma-related GEP literature, and/or experience with appropriate use criteria (AUC) consensus development was convened to systematically review the available evidence surrounding CLIAcertified GEP diagnostic and prognostic tests. The objective of this expert panel was to develop a set of consensus-based AUC recommendations to guide the integration of GEP technology into the diagnosis and management of melanoma in specificallydefined situations commonly encountered in clinical practice.
Selection of GEP Assays for Inclusion
It was specified a priori that these recommendations would pertain to clinically diagnostic, histologically diagnostic, or prognostic GEP assays for melanoma that were validated, US governmentally approved for clinical use, readily available, and with existing widespread usage at the time the expert panel was convened. This led to selection of three GEP assays which met inclusion criteria: the 2-GEP test 6 (Pigmented Lesion Assay, DermTech, La Jolla, CA), the 23-GEP test 5 (myPath®, Myriad Genetics, Inc., Salt Lake City, UT), and the 31-GEP test 4 (DecisionDx™-Melanoma, Castle Biosciences, Inc., Friendswood, TX).
GEP augmenting melanoma clinical diagnosis
The 2-GEP test is an adjunctive diagnostic assay used to aid the clinician in the decision to biopsy in cases of clinically and/or dermoscopically equivocal pigmented lesions. Genetic material (in the form of RNA) is harvested from the lesion in question by an adhesive patch. The RNA is then reverse-transcribed to DNA and amplified using qRT-PCR to determine RNA expression levels of two key genes: long intergenic non-protein coding RNA 518 (LINC00518) and melanoma antigen preferentially expressed in tumors (PRAME). 6 The method is non-invasive and yields a low, moderate, or high-risk result for each lesion tested. This result is then considered in the context of lesion morphology, clinical history, and data from other adjunctive tests to determine if biopsy or continued observation is warranted. specimens and qRT-PCR is used to assess expression of 23 key genes. These genes, involved in cell differentiation, cell-cell signaling, and immune response, have expression patterns which vary between benign nevi and malignant melanoma in a predictable manner. The results are combined into a single score ranging from -16.7 through 11.1, with groupings corresponding to benign, indeterminate, or consistent with malignant melanoma. 5 
GEP augmenting assessment of melanoma prognosis
The 31-GEP test, as opposed to the 2-GEP and 23-GEP assays, is used to help determine prognosis in patients with earlystage invasive cutaneous melanoma. After extraction of RNA from formalin-fixed, paraffin-embedded excision specimens of primary melanoma, the level of expression of 31 genes (28 prognostic genes) is quantified using qRT-PCR and used to stratify patients into low-risk (Class 1a and 1b) and high-risk (Class 2a and 2b) groups based on probability of subsequent metastasis. 13, 14 The results of this test have been shown to be synergistic with existing risk-stratification tools identifying patients with high-risk tumors. 13, 15 Literature Search A thorough systematic review of the literature pertaining to the use of the 2-, 23-, and 31-GEP tests was conducted. The goal of this search was to identify studies evaluating either clinical validity, outcomes, or utility for level of evidence review and development of recommendations by the expert panel. The Medline database was queried for all relevant articles published between 1940 and 2018 using exploded MeSH terms and keywords pertaining to the following themes: gene expression profiling, diagnosis, prognosis, and molecular genomics. The Boolean term "AND" was used to find the intersection of these themes with the term "cutaneous melanomas."
The initial search identified potentially relevant articles, which were each distributed to reviewers who independently screened for relevance and appropriateness for inclusion. The articles that remained were then assessed in depth to determine relevance to the study objective and final eligibility. Discrepancies between the independent reviewers were resolved through team discussion. Articles deemed relevant to one of the three GEP tests being evaluated based on full-text review were selected for level of evidence analysis by members of the consensus panel.
Development of Consensus-Based AUC Recommendations
An initial list of potential indications for the use of each GEP test was created based on review of the pertinent articles identified through the literature search as well as the clinical experience of a core group of experts. This list was meant to encompass a broad selection of clinical scenarios commonly faced by practicing dermatologic surgeons and dermatopathologists in the diagnosis and management of melanocytic lesions. The purpose was to identify common scenarios in which utilization of GEP tests might be considered so that the existing literature could be assessed for evidence supporting or refuting their use in each situation. This list was not meant to be inclusive of every possible situation for which the use of the 2-, 23-, or 31-GEP tests could be considered, but was meant to cover a wide range of the most common scenarios. After initial creation of the list of indications for each GEP assay, each member of the consensus panel had an opportunity to review and propose modifications of the draft indications.
Level of Evidence Assessment and Consensus Recommendation Process
A consensus panel of nine expert dermatologists/dermatologic surgeons/dermatopathologists selected for their knowledge of the tests being evaluated and the associated literature, their expertise in managing pigmented lesions, and/or their recognized academic excellence was convened in person in August 2018, to determine the individual level of evidence for each of the selected publications as well as an overall strength of recommendation for each indication using standard Strength of Recommendation Taxonomy (SORT) methodology. 16 The selected articles were made available for individual review prior to the consensus meeting. Additionally, a reference offering an overview of the SORT framework 16 was provided and a brief lecture on evidence-based medicine and SORT methodology was delivered to members of the expert panel.
Consensus
among panel members regarding level of evidence for each article and strength of recommendation for each recommendation was achieved using a modified Delphi technique. 17 This methodology has been used extensively in the literature to yield recommendations for dermatologists. [18] [19] [20] Consensus was defined as agreement among at least a supermajority of 2/3 of the experts participating in the panel. If 2/3 agreement could not be achieved, the proposal was rediscussed among panel members and modified until agreement was achieved.
Comprehensive Literature Search
The initial literature search produced 524 articles. After review of articles deemed potentially relevant, 33 articles which measured the clinical validity, relevance, efficacy, and/or utility of the GEP tests were designated for distribution to the full consensus panel. Of the 33 relevant published articles identified, 8 pertained to the 2-GEP test 6,21-27 , 10 were pertinent to the 23-GEP test 5, 7, [28] [29] [30] [31] [32] [33] [34] [35] , and 15 were germane to the 31-GEP test [13] [14] [15] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] (Tables  1-3) .
Levels of Evidence of Selected Articles
Where applicable, SORT guidelines were utilized to assign a level of evidence to each article based on consensus of the expert panel as outlined previously (Tables 1-3 ). Of the 8 articles pertaining to the 2-GEP test, 2 were determined by expert panel consensus to represent Level 3 evidence 25,26 , 2 were deemed consistent with Level 2 evidence 21, 22 , and 2 were felt to represent Level 1 evidence 6, 23 . Two articles were not assigned levels of evidence because after group discussion, consensus deemed their content irrelevant to the generated list of recommendations. 10, 27 Based on the consensus of the expert panel, 2 of the 10 articles pertaining to the 23-GEP test were felt to represent Level 3 evidence 33,35 , 4 were deemed to be consistent with Level 2 evidence 7,30,31,34 , and 3 were determined to be Level 1 evidence. 5, 29, 32 One article was not assigned a level of evidence because it was deemed irrelevant to the current study. 28
RESULTS
Regarding the published articles detailing the 31-GEP test, 3 out of 15 were deemed to represent Level 3 evidence 37,40,46 , 9 were classified as Level 2 evidence 14, 15, 36, 38, 41, 42, 44, 45, 47 , and 2 graded as Level 1 evidence 13, 43 . Upon discussion by the expert panel, 1 article was deemed to be outside of the context of the panel and thus was not assigned a level of evidence. 39 Overall, consensus opinion was reached on the strength of recommendation for 29 recommendations involving the use of diagnostic and prognostic gene expression profiling tests in the diagnosis and management of melanoma (Tables 4-6) .
Consensus-Based AUC Recommendations for the 2-GEP Test
Of the 7 recommendations considered for the 2-GEP test (Table 4 ), 1 was deemed to represent a B-strength recommendation for the use of the 2-GEP assay:
• Cases in which patients present with atypical lesions requiring additional assessment beyond inspection in order to aid in the biopsy decision This study is significant because it represents the first set of expert consensusbased AUC recommendations developed for the usage of diagnostic and prognostic gene expression profiles in the management of suspicious pigmented/melanocytic lesions and biopsy-proven melanoma. The recommendations offered herein stratify the strength of evidence available for commonly encountered potential indications for the three validated, CLIA-certified, readily available GEP tests currently available for use in the diagnosis and management of malignant melanoma. Previous guidelines have either not commented on the use of GEP assays 48 or have made broad statements concerning diagnostic and prognostic genetic tests without offering any detailed discussion about defined use in DISCUSSION specific clinical situations. 12 Given that these diagnostic and prognostic GEP assays are clinically available and are each already being used in over 10,000 cases per year [8] [9] [10] [11] , it is critical to provide clinicians with a set of evidence-based criteria to help ensure that these tests are used for clinically indicated situations.
It is imperative that practicing clinicians interpreting these consensus-based recommendations understand the underlying methodology, which led to their creation. The expert consensus panel that determined the strength of each recommendation for GEP usage understood that not all cases encountered in the clinical setting will align perfectly with these pre-defined scenarios. These recommendations are meant to provide a framework that can be applied to the majority of clinical scenarios and which can be used as a starting point to provoke thoughtful decision making in situations not specifically defined by the evaluated scenarios. This aligns with the original definition of evidence-based medicine, which notes the individual clinician's responsibility in critically appraising the literature to permit thoughtful case-specific decision making and assist in patient counseling. 49 It is also important that clinicians have an appropriate understanding of the meaning of each recommendation grade as defined by the SORT taxonomy. 16 Although an Astrength recommendation represents the highest level of support, even a C-strength recommendation (typically based upon disease-oriented evidence, expert opinion or usual practice) does provide appropriate direction for use in specific situations. Studies rated as B or C level evidence are generally accepted as appropriate for establishing clinical recommendations when A level evidence is not available.
Along these lines, the juxtaposition of the dynamic nature of research with the often static nature of AUC recommendation statements must be considered when interpreting these findings. It therefore must be understood by clinicians utilizing these recommendations that the body of available evidence is not static and is constantly evolving. Often, governmental bodies and large agencies lag in recognizing the value of new technologies because of lengthy review processes and delays in academic publishing. This study attempted to mitigate these complications by providing the most up-to-date body of evidence, including articles published even a week before the consensus panel was convened. In such a rapidly evolving field, the impetus for this panel was to make recommendations that will affect current dermatologist management.
However, the expert consensus panel that developed these recommendations understands and is optimistic that research in this field will continue to evolve. It is therefore the hope of the panel that these recommendations will be updated as new evidence emerges.
There are several limitations to this study. Only 3 GEP tests were considered because they are the only validated, CLIA-certified, and widely used tests currently available. Other tests may be available in the future that may supersede the efficacy of the current tests.
An additional limitation, consistent with most publications focusing on recommendations, is that the panel did not consider costs in the analysis. This would have been difficult as healthcare costs in the United States depend on a variety of factors including market factors and policies inherent to specific insurance plans. However, several studies have been published supporting the cost-effectiveness of these tests, 24, 50 and more will likely be undertaken in the future. In addition, in many situations, GEP tests are now covered by Medicare and other insurance plans, and assistance from industry is often available, capping the associated costs and facilitating the accessibility of these assays to patients in need.
These expert consensus-based AUC recommendations present an evidencebased framework developed through systematic literature review and expert consensus for applying diagnostic and prognostic GEP tests to the management of melanoma patients. Clinical judgment should be applied to the use of these recommendations, and decisions regarding the use of GEP should be made on an individual, case-by-case basis. Additional studies aiming to fill these gaps will refine these findings and will be important in the development of updated consensus recommendations.
These expert panel consensus-based AUC recommendations have been developed for the purpose of guiding clinical decision making regarding the use of gene expression profiles in the management of malignant melanoma. It should be recognized that these consensus-based recommendations are based on the best available evidence at the time that these recommendations were made, in combination with expert opinion. These recommendations are intended to be fluid and may evolve over time as new gene expression evidence profile tests become available and as new evidence regarding existing assays is published. These recommendations are not all-inclusive and should not be expected to definitively address all possible clinical situations faced by dermatologists and dermatologic surgeons. These recommendations were developed with the intent of aiding clinical decision making, but the final judgment as to the utility of any specific diagnostic or prognostic test in a specific situation must be made by the managing physician while considering all data available. For the dermatologist to request after ambiguous pathology report C a Based on SORT Taxonomy, A = Consistent, good-quality patient-oriented evidence, B = Inconsistent or limitedquality patient-oriented evidence, C = Consensus, disease-oriented evidence, usual practice, expert opinion, or case series 
